LoQus23 Therapeutics announces £35 million (c.$43 million) Series A financing to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease

Posted on by

Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.